Back to results
US 7,638,326 B2Granted
Activation and expansion of T-cells using an engineered multivalent signaling platform
AssigneeThe Trustees of the University of Pennsylvania
InventorsCarl June, James Riley, Marcela Maus, Anna Thomas, Robert Vonderheide
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.
Claims15
An engineered multivalent signaling platform (EMSP) comprising a K562 cell line for use in long term expansion of T cells, wherein said K562 comprises on its surface:
- at least one molecule that is capable of stimulating a primary signal to the T cell, wherein said at least one molecule is an exogenous antibody that binds to CD2;
- a ligand for CD28, wherein said ligand for CD28 is capable of cross-linking CD28 on T cells and delivering a secondary signal to said T cells, wherein said ligand is selected from the group consisting of anti-CD28 antibody, CD80, and CD86;
- and wherein said EMSP is further genetically modified to express the co-stimulatory molecule, 4-1BBL.
Dependencies are inferred from the claim text.